financetom
Business
financetom
/
Business
/
Core Scientific Insider Sold Shares Worth $1,892,572, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Core Scientific Insider Sold Shares Worth $1,892,572, According to a Recent SEC Filing
Jan 6, 2025 12:41 AM

03:20 AM EST, 01/06/2025 (MT Newswires) -- Todd M Duchene, Chief Legal and Administrative Officer, on December 31, 2024, sold 132,810 shares in Core Scientific ( CORZ ) for $1,892,572. Following the Form 4 filing with the SEC, Duchene has control over a total of 2,048,700 shares of the company, with 2,048,700 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1839341/000090514825000029/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Secure Energy Extends $800 Million Credit Facility Until May 2027
Secure Energy Extends $800 Million Credit Facility Until May 2027
Jun 3, 2024
08:06 AM EDT, 06/03/2024 (MT Newswires) -- Secure Energy Services ( SECYF ) on Monday said it has amended the credit agreement for its $800 million senior secured revolving credit facility, extending the maturity until May 31, 2027. As of May 31, the facility remains undrawn, excluding outstanding letters of credit, the company said. Together with our $300 million of...
Top Premarket Gainers
Top Premarket Gainers
Jun 3, 2024
08:05 AM EDT, 06/03/2024 (MT Newswires) -- GameStop ( GME ) shares surged 77% in recent Monday premarket activity, after trader Keith Gill apparently posted on his Reddit account Roaring Kitty Sunday a screenshot showing he placed a $116 million bet on the game retailer's stock. MingZhu Logistics Holdings ( YGMZ ) stock rose more than 48%, after saying Friday...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Jun 3, 2024
June 3 (Reuters) - Moderna ( MRNA ) and partner Merck & Co ( MRK ) said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer. Detailed data on Monday from the 157-patient trial showed that after two...
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial
Jun 3, 2024
07:59 AM EDT, 06/03/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Monday that its experimental drug, TAK-861, to treat narcolepsy type 1 demonstrated statistically significant and clinically meaningful improvements across primary and secondary endpoints in a phase 2b trial. The treatment demonstrated increases in sleep latency on the maintenance of wakefulness test versus placebo sustained over 8 weeks,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved